Search research articles
Contact Us
Filters
Showing results (81-90 of 108) with videos related to
Page
of 11
Sort By:
The Lancet. Respiratory Medicine
|
April 9, 2021
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study
Timothy A Yap, Kazuhiko Nakagawa, Nobukazu Fujimoto, et al.
Cancers
|
December 23, 2022
The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study
Tomoka Nishimura, Eiki Ichihara, Toshihide Yokoyama, et al.
Cancer Science
|
December 4, 2023
Nationwide prospective registry database of patients with newly diagnosed untreated pleural mesothelioma in Japan
Seiki Hasegawa, Yasushi Shintani, Teruhisa Takuwa, et al.
International Journal of Clinical Oncology
|
August 28, 2025
Impact of antibiotic use on survival in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitor and chemotherapy
Nobuaki Ochi, Eiki Ichihara, Toshihide Yokoyama, et al.
Cancer Research
|
April 19, 2006
High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras
Marie Wislez, Nobukazu Fujimoto, Julie G Izzo, et al.
Japanese Journal of Clinical Oncology
|
April 10, 2024
A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL)
Naoyuki Nogami, Toshio Kubo, Akihiro Bessho, et al.
JTO Clinical and Research Reports
|
September 30, 2021
Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma
Kazuhiko Nakagawa, Takashi Kijima, Morihito Okada, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 2, 2017
A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202
Shoichi Kuyama, Nobuaki Ochi, Akihiro Bessho, et al.
Cancers
|
December 17, 2024
Frequency and Significance of Body Weight Loss During Immunochemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
Masataka Taoka, Eiki Ichihara, Toshihide Yokoyama, et al.
Japanese Journal of Clinical Oncology
|
June 11, 2021
Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404
Takashi Ninomiya, Naoyuki Nogami, Toshiyuki Kozuki, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 108) with videos related to
Sort By:
Page
of 11
The Lancet. Respiratory Medicine
|
April 9, 2021
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study
Timothy A Yap, Kazuhiko Nakagawa, Nobukazu Fujimoto, et al.
Cancers
|
December 23, 2022
The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study
Tomoka Nishimura, Eiki Ichihara, Toshihide Yokoyama, et al.
Cancer Science
|
December 4, 2023
Nationwide prospective registry database of patients with newly diagnosed untreated pleural mesothelioma in Japan
Seiki Hasegawa, Yasushi Shintani, Teruhisa Takuwa, et al.
International Journal of Clinical Oncology
|
August 28, 2025
Impact of antibiotic use on survival in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitor and chemotherapy
Nobuaki Ochi, Eiki Ichihara, Toshihide Yokoyama, et al.
Cancer Research
|
April 19, 2006
High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras
Marie Wislez, Nobukazu Fujimoto, Julie G Izzo, et al.
Japanese Journal of Clinical Oncology
|
April 10, 2024
A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL)
Naoyuki Nogami, Toshio Kubo, Akihiro Bessho, et al.
JTO Clinical and Research Reports
|
September 30, 2021
Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma
Kazuhiko Nakagawa, Takashi Kijima, Morihito Okada, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 2, 2017
A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202
Shoichi Kuyama, Nobuaki Ochi, Akihiro Bessho, et al.
Cancers
|
December 17, 2024
Frequency and Significance of Body Weight Loss During Immunochemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
Masataka Taoka, Eiki Ichihara, Toshihide Yokoyama, et al.
Japanese Journal of Clinical Oncology
|
June 11, 2021
Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404
Takashi Ninomiya, Naoyuki Nogami, Toshiyuki Kozuki, et al.
Page
of 11